Shanghai Kehua Bio-engineering (002022.SZ): The hepatitis C virus (HCV) nucleic acid detection kit (PCR-fluorescence method) has obtained a medical device registration certificate.

Shanghai Kehua Bio-engineering (002022.SZ) announced that its holding subsidiary, Suzhou Tianlong Bio-technology Co., Ltd., has received a medical device registration certificate (in vitro diagnostic reagent) issued by the National Medical Products Administration. The product involved is the "Hepatitis C Virus (HCV) Nucleic Acid Detection Kit (PCR-fluorescence method)". This product is used for quantitatively detecting Hepatitis C Virus nucleic acid (RNA) in human serum or plasma samples.